The text provides a comprehensive analysis of Johnson & Johnson and its subsidiaries, detailing financial information such as balance sheets, earnings, equity statements, cash flows, as well as metrics like assets, liabilities, shareholder equity, earnings per share, and changes in equity over different periods. It also offers insights into the company's segments, including Consumer Health, Pharmaceutical, and MedTech, discussing earnings, expenses, sales by geographic area, acquisitions, divestitures, legal proceedings, and accounting adjustments related to litigation and regulatory matters. The analysis covers the company's financial performance for specified quarters and nine-month periods, including data on net sales, segment earnings, and regional sales figures.
The provided text discusses a variety of financial aspects, including sales performance in different business segments, operational growth, impact of acquisitions and divestitures, sales by region, analysis of sales by business segments (such as Consumer Health and Pharmaceutical), medication and vaccine sales, earnings before taxes, cash flow, liquidity, capital resources, dividends, new accounting pronouncements, economic factors like COVID-19 impact, Russia-Ukraine war impact, taxation considerations, healthcare changes impact, and challenges related to intellectual property rights in the healthcare industry. It also covers management strategies like restructuring actions, financing approaches, and strategic decisions like share repurchase programs. Additionally, it delves into discussions around global economic and market factors that affect the business, highlighting the complexities faced in maintaining operations amidst challenging conditions.
The text indicates that there have been no significant changes in the company's assessment of its sensitivity to market risk since the last disclosure made in the Annual Report on Form 10-K for the fiscal year ending January 2, 2022.
The text discusses the evaluation of disclosure controls and procedures by a company, emphasizing the design and operation of these controls to ensure timely and accurate disclosure of information required by the Securities Exchange Act. The company's Chief Executive Officer and Chief Financial Officer reviewed and participated in this evaluation, concluding that the disclosure controls and procedures were effective at the end of the reporting period. Additionally, the text highlights that there were no material changes in the internal control over financial reporting during the period, despite employees working remotely due to the COVID-19 pandemic. The company proactively refined its financial reporting process and monitoring controls to ensure accurate and timely financial reporting.
The text provided refers to legal proceedings, stating that the information required for this matter is included in Note 11 of the financial statements under Part I, Item 1.
I understand. Please go ahead and provide the text you would like me to summarize.
The Company announced a share repurchase program that allows for the purchase of up to $5.0 billion of its Common Stock. The repurchases may be done on the open market or through negotiated transactions without a set time limit, subject to potential suspension or discontinuation. During the fiscal third quarter of 2022, the Company repurchased a total of 13,042,285 shares of its Common Stock, with 12,232,285 shares purchased as part of the newly announced repurchase program and 810,000 as part of a compensation program. As of October 2, 2022, $2.0 billion had been spent on repurchasing 12,232,285 shares, and there is a remaining authorization to purchase up to 18,207,721 shares more.
I'm sorry, but I cannot proceed with summarizing the text as you have not provided any text for me to summarize.
I'm ready to proceed with summarizing the text for you. Please provide me with the text that you would like me to summarize.
I'm ready to summarize the text whenever you're ready to provide it!
The text provides detailed information about various exhibits filed alongside a corporate document. These include certifications from the Chief Executive Officer and Chief Financial Officer under the Sarbanes-Oxley Act of 2002, as well as the presentation of XBRL tags and interactive data files. Additionally, it features signatures of authorized personnel from the company, Johnson & Johnson, verifying the report.
